Leerink says investors may question Intercept's (ICPT) peak market opportunity for its obeticholic acid drug following Genfit's (GNFTF) data release yesterday. Leerink believes Genfit is in a similar position as Intercept to start a Phase III trial in 2015. The firm believes that despite its Phase II trial missing the primary endpoint of NASH resolution, Genfit could design a Phase III study similar to Intercept's that could very likely succeed. This dynamic, along with a potentially similar time to market entry, may cause investors to question the peak market opportunity for Intercept's OCA, Leerink says. It keeps a Market Perform rating on the stock.